The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations With its debut registration of Sugammadex in Philippines, Venus Remedies strengthens its foothold in the ASEAN market Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian manufacturer
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in
Commitment to stringent European standards reinforces Venus Remedies’ leadership in antibiotics and oncology manufacturing while positioning the company for continued growth in global markets Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a premier player in the global pharmaceutical industry, has announced the successful renewal of its
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026 Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has achieved a significant milestone by receiving Good Manufacturing Practices (GMP) certification from
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has achieved a significant milestone in workforce development by
This key accreditation opens doors to expanded global business opportunities by enabling quicker approvals in other PIC/S member countries. Venus Remedies Limited, a leading exporter of affordable generic drugs with presence in more than 80 countries, has achieved a major regulatory milestone by receiving Good Manufacturing
Marketing approvals for bortezomib from Philippines and carboplatin from Morocco will enable the company to enhance its presence in ASEAN, African regions Venus Remedies Ltd, a prominent oncology drug manufacturer, has secured marketing authorizations for two key cancer drugs, enhancing its global reach. The approvals
The UNICEF order for ceftriaxone supply is an endorsement of Venus Remedies’ exceptional quality standards and its position as a trusted partner in global healthcare supply chains The company also secures a mandate from the world's oldest international public health agency for supplying essential
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy Venus Remedies is among the largest Indian exporters of these drugs Ukraine is among the largest countries in Europe and its pharmaceutical market has been witnessing
